Q-omics provides the consensus-scored CNOT6L profile across patient tissues and cancer cell-line models. CNOT6L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNOT6L is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, CNOT6L RNA expression shows 21,206 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LUAD, and ACC as cancer lineages where CNOT6L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNOT6L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNOT6L survival associations across molecular data types. CNOT6L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNOT6L RNA expression–survival associations across cancer types. High CNOT6L expression shows unfavorable associations in UVM and ACC, but favorable associations in KIRC, HNSC, SKCM and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNOT6L RNA expression.
This table summarizes CNOT6L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CNOT6L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNOT6L shows lower tumor expression in LUAD, KICH, UCEC, THCA and LUSC and higher tumor expression in CHOL. The LUAD box plot shows higher CNOT6L RNA expression in normal versus tumor tissue (log2 FC = −0.754, t-test p < 0.001).
This table shows molecular features associated with CNOT6L in patient tissues and cancer cell lines. In patient samples, CNOT6L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CNOT6L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
